January 22, 2026 (Global) – Medtronic plc has announced a $90 million strategic investment in Anteris Technologies, the developer behind the novel DurAVR Transcatheter Heart Valve (THV) System, strengthening its commitment to innovation in transcatheter aortic valve replacement (TAVR) therapy. The move comes as Medtronic looks to expand its structural heart portfolio while supporting the clinical and commercial development of differentiated valve technologies.
Anteris, headquartered in Minnesota with global operations, is known for its DurAVR THV, a biomimetic balloon-expandable heart valve designed to mimic the performance of a healthy aortic valve. Medtronic’s investment follows Anteris’ underwritten public stock offering, which helped generate a combined $320 million in gross proceeds to support ongoing research, clinical trials, and development initiatives.
“This strategic investment, along with our underwritten offering of common stock, represent an important milestone for our company,” said Wayne Paterson, Vice Chairman and CEO of Anteris. “It also provides strong validation of our program from the capital markets and a major strategic innovator.”
The capital infusion will support the execution of the PARADIGM global pivotal trial — a prospective randomized controlled study evaluating the safety and effectiveness of the DurAVR THV compared to commercially available TAVR devices. This funding is critical as Anteris advances toward regulatory milestones and broader clinical adoption.
Key Highlights of the Investment
- Medtronic committed $90 million in a strategic investment in Anteris Technologies, a leader in novel TAVR device development.
- The investment followed Anteris’ underwritten public stock offering, bringing total combined gross proceeds to approximately $320 million.
- Funds will support the PARADIGM pivotal trial, designed to compare the DurAVR THV system against existing TAVR therapies.
- DurAVR’s biomimetic design aims to replicate the performance of a healthy aortic valve using patented anti-calcification ADAPT tissue.
- The investment reflects Medtronic’s ongoing commitment to advancing structural heart innovation and expanding its TAVR portfolio.
Industry analysts view the investment as a clear signal of the continued strategic importance of TAVR technologies within the cardiovascular device landscape. With an aging global population and strong demand for minimally invasive structural heart therapies, capital commitments like this could accelerate clinical development and broaden patient access to next-generation treatment options.
